Cardiology News / Recent Literature Review / Second Quarter 2021
ESC Digital Congress 27-30/8/2021
TCT Meeting, San Francisco, 22-26/10/2021
42ndPanhellenic Congress of Cardiology, Athens, 21-23/10/21
AHA Scientific Sessions 2021, Boston, MA, USA, 13-15/10/21
ACC.22, Washington, DC, USA, 2-4/4/22
EuroPCR, Paris, France, 17-20/5/22
Systemic Lupus Erythematosus (SLE) Patients Have a Higher Associated Risk of Heart Failure (HF) and Other Cardiovascular (CV) Outcomes Compared with Matched Control Subjects
Among 3,411 SLE patients (median age: 44.6 years; 86% women) who were matched with 13,644 controls, over a median of 8.5 years, absolute 10-year risks of outcomes were: HF, 3.71% vs 1.94%; atrial fibrillation, 4.35% vs 2.82%; ischemic stroke, 3.75% vs 1.92%; MI, 2.17% vs 1.49%; venous thromboembolism, 6.03% vs 1.68%; and the composite of ICD implantation/ventricular arrhythmias/cardiac arrest, 0.89% vs 0.30% (SLE patients, vs control subjects). SLE with subsequent HF was associated with higher mortality compared with HF without SLE (adjusted hazard ratio: 1.50) (Yafasova A et al, J Am Coll Cardiol 2021;77:1717-27).
Worse Long-Term Outcomes of Patients with Late Presentation of ST-Segment Elevation Myocardial Infarction (STEMI)
Of 13,707 patients (2011-2015), 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset were categorized as late (12-48 h; n = 624) or early (<12 h; n = 5,202) presenters. Late presenters had worse clinical outcomes (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at ≥12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures decreased from the first (<12 h) to the second (12-24 h) 12-h interval of symptom-to-door time (“no primary PCI strategy” increased from 4.9% to 12.4%, and “no PCI” from 2.3% to 6.6%; both p < 0.001). Mortality rates increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05) (Cho KH et al, J Am Coll Cardiol 2021;77:1859-70).
High Dietary Sodium (HS) Intake Increases Plasma Volume, Lowers Standing Plasma Norepinephrine, and Decreases Δ Heart Rate in Patients With Postural Tachycardia Syndrome (POTS)
Among 14 POTS patients and 13 healthy control subjects (HC), age 23-49 years, enrolled in a crossover study with 6 days of low (LS) (10 mEq/d) or high sodium (HS) (300 mEq/d) diet, in POTS, the HS diet reduced upright heart rate and Δ heart rate compared with the LS diet. Total blood volume and plasma volume (PV) increased, and standing norepinephrine decreased with the HS compared with the LS diet. However, upright heart rate, Δ heart rate, and upright norepinephrine remained higher in POTS than in controls on the HS diet, despite no difference in the measured PV (Garland EM et al, J Am Coll Cardiol 2021; 77:2174-84)... (excerpt)
- 2021-07-17 (2)
- 2021-07-03 (1)
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).